Mesothelioma treatment typically combines multiple approaches, including immunotherapy, chemotherapy, surgery, and radiation, tailored to the cancer’s location, cell type, and stage. The specific combination you receive depends heavily on whether the tumor can be surgically removed and which of the three cell types (epithelioid, sarcomatoid, or biphasic) your biopsy reveals. Five-year survival rates range from 23% for localized disease down to 11% for distant spread, but outcomes are improving as immunotherapy and modern multimodal strategies become standard.
First-Line Treatment: Immunotherapy
The treatment landscape for mesothelioma shifted significantly in 2020 when the FDA approved a combination of two immune checkpoint inhibitors (nivolumab plus ipilimumab) as a first-line option for unresectable pleural mesothelioma. In the pivotal trial, patients receiving this combination lived a median of 18.1 months compared to 14.1 months with chemotherapy alone. The most recent ASCO guidelines now recommend this immunotherapy combination as a first-line option for all newly diagnosed pleural mesothelioma, regardless of cell type.
For nonepithelioid subtypes (sarcomatoid and biphasic), which historically respond poorly to chemotherapy, immunotherapy is the clear preferred choice. Current guidelines advise against offering chemotherapy alone to these patients unless they have medical reasons that prevent immunotherapy use. Treatment continues for up to two years as long as the cancer isn’t progressing and side effects remain manageable.
A newer option combines immunotherapy with chemotherapy. This approach pairs a different checkpoint inhibitor (pembrolizumab) with the standard chemotherapy drugs, and guidelines now list it as another strong first-line choice for both epithelioid and nonepithelioid types.
Chemotherapy as a Treatment Option
For patients with epithelioid mesothelioma who aren’t receiving immunotherapy, the standard chemotherapy regimen pairs pemetrexed with a platinum-based drug, most commonly cisplatin. Treatments are given intravenously once every 21 days. If cisplatin’s side effects are too harsh, carboplatin is used as a substitute. A blood vessel growth inhibitor (bevacizumab) can be added to this combination for additional benefit in epithelioid cases.
The most significant side effect of these regimens is a drop in infection-fighting white blood cells, which occurs at severe levels in roughly 24% of patients on the cisplatin combination and 36% on carboplatin. Your oncology team will monitor blood counts regularly and may adjust dosing or delay cycles if counts fall too low.
When Surgery Is an Option
Surgery is not offered to every mesothelioma patient. Current guidelines are explicit: surgical removal should only be considered for highly selected patients with early-stage (T1-3, no lymph node involvement) epithelioid tumors. Patients with sarcomatoid mesothelioma should not be offered major surgery, as it has not shown benefit for that cell type.
When surgery is appropriate, there are two main procedures. The more extensive one, extrapleural pneumonectomy, removes the entire affected lung along with the lining of the chest wall, the diaphragm, and the heart sac on that side. The less radical option, pleurectomy/decortication, strips away the diseased lining and all visible tumor while preserving the lung. An “extended” version of this second procedure also removes the diaphragm or heart sac if needed.
The lung-sparing approach carries considerably lower risk. Across multiple studies, surgical mortality for pleurectomy/decortication ranges from 2% to 4%, while extrapleural pneumonectomy ranges from 6% to 10.5%. Keeping the lung also means fewer heart and breathing complications during recovery. Based on this evidence, the lung-sparing procedure has become the more common choice at experienced centers.
Multimodal Therapy: Combining Treatments
The best outcomes for surgical candidates come from combining surgery with chemotherapy and radiation. A study comparing modern trimodal therapy (lung-sparing surgery, platinum/pemetrexed chemotherapy, and intensity-modulated radiation) to older approaches found median survival of 20.2 months versus 12.3 months. Two-year survival reached 42% with the modern approach compared to lower rates with surgery and conventional radiation alone. Ninety percent of patients in the modern group also received chemotherapy, reinforcing that surgery works best as part of a coordinated plan rather than a standalone treatment.
Treating Peritoneal Mesothelioma
Mesothelioma that develops in the abdominal lining is treated differently from the pleural form. The primary approach combines aggressive surgical removal of visible tumor with heated chemotherapy delivered directly into the abdomen during the operation. This procedure, known as HIPEC, involves bathing the abdominal cavity in a heated chemotherapy solution at about 40°C (104°F) for 90 minutes.
Outcomes depend heavily on how completely the surgeon removes visible disease. When all visible tumor is cleared, median survival reaches approximately 10.6 years, a remarkably different trajectory from incomplete removal, where survival drops to under a year. For the overall group of peritoneal mesothelioma patients treated this way, median survival is about 3.3 years.
Patients who undergo a second procedure when disease returns also fare better, with median survival of nearly 5.6 years from the first operation compared to 3 years for those who have only one. The type of chemotherapy solution matters too: platinum-based solutions produced median survival of 42.4 months versus 11.6 months for older alternatives.
Managing Fluid Buildup and Symptoms
Pleural effusion, the accumulation of fluid between the lung and chest wall, is one of the most common and distressing symptoms of pleural mesothelioma. It causes progressive shortness of breath and chest pressure. Two main approaches address it.
A tunneled pleural catheter is a small tube placed through the chest wall that allows fluid to be drained at home, typically by you or a caregiver, several times a week. This approach is effective: 91% of patients who receive one never need another fluid-draining procedure. The complication rate is low, around 4.8%. In about a quarter of cases, the two layers of the lung lining eventually seal together on their own (spontaneous pleurodesis), allowing the catheter to be removed after a median of 44 days. This rate rises to 36% when the catheter is placed in an operating room setting.
The alternative is chemical pleurodesis, where an irritating substance is introduced into the pleural space to intentionally scar the two layers together and prevent fluid from reaccumulating. This is typically done during a hospital stay and works best when the lung can fully re-expand.
Genetic Testing and Emerging Options
All mesothelioma patients should be offered germline genetic testing. This isn’t just about understanding your personal cancer risk or implications for family members. Certain genetic profiles can open the door to targeted therapies or help determine which treatments are most likely to work.
Clinical trials are actively testing new approaches, including CAR-T cell therapy, where a patient’s own immune cells are engineered to recognize and attack mesothelioma cells. Early-phase trials are targeting mesothelin, a protein found on the surface of mesothelioma cells, by delivering modified immune cells directly into the chest cavity through a catheter. These trials are still in Phase 1, meaning they’re establishing safety and dosing rather than confirming effectiveness, but they represent a fundamentally different strategy from existing treatments.
Tumor Treating Fields, a wearable device that uses electric fields to disrupt cancer cell division, is another non-invasive option that has been explored for mesothelioma and is generally well tolerated. Your oncologist can help determine whether any active trials match your specific diagnosis and stage.